A Phase I, Multicenter, Open-label Study of TY-2136b, Administered Orally in Patients With Advanced or Metastatic Solid Tumors Harboring ALK, ROS1 or NTRK1-3 Alterations
This study tests an experimental cancer medication called TY-2136b in people with advanced solid tumors. Researchers want to find the safest and most effective dose of this new targeted treatment.
You may be able to join if you are 18 or older with an advanced solid tumor that has specific genetic changes known as ALK, ROS1, or NTRK1-3. Standard treatments must have stopped working for you, or are not a good option.
Participants will take the study medication by mouth as doctors carefully monitor their health and check for any side effects. The goal is to see how the body handles the medicine and determine the right dose for future studies.
This study takes place at medical centers in Providence, Rhode Island, and Houston, Texas. The current status of the study is not specified, so you will want to contact the study team for the latest updates.
- 1Tests a new targeted oral medication called TY-2136b.
- 2Designed for adults with specific genetic changes in their tumors.
- 3Locations include research centers in Rhode Island and Texas.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.